Replies to post #111066 on Biotech Values

[blackcat]

A bit more from Barclays

Barclays Capital analysts Richard Silver and Ann Trimble believe that Copaxone's market share for new prescriptions fell to 29% during November from a monthly average of 30-45% in preceding months.

There is a stat error in this article which certainly favors NVS/TEVA.

http://www.globes.co.il/serveen/globes/docview.asp?did=1000609419&fid=1725